Search results
Results From The WOW.Com Content Network
The treatment of latent tuberculosis infection (LTBI) is essential to controlling and eliminating TB by reducing the risk that TB infection will progress to disease. Latent tuberculosis will convert to active tuberculosis in 10% of cases (or more in cases of immune compromised patients).
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
According to the US guidelines, latent tuberculosis infection diagnosis and treatment is considered for any BCG-vaccinated person whose skin test is 10 mm or greater, if any of these circumstances are present: [citation needed] Was in contact with another person with infectious TB; Was born or has lived in a high TB prevalence country
[1] [9] People with latent TB do not spread the disease. [1] Active infection occurs more often in people with HIV/AIDS and in those who smoke. [1] Diagnosis of active TB is based on chest X-rays, as well as microscopic examination and culture of bodily fluids. [10] Diagnosis of latent TB relies on the tuberculin skin test (TST) or blood tests ...
Nodules and fibrotic scars may contain slowly multiplying tubercle bacilli with the potential for future progression to active tuberculosis. [1] Persons with these findings, if they have a positive tuberculin skin test reaction, should be considered high-priority candidates for treatment of latent infection regardless of age.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
According to a 2013 review, tuberculosis elimination will require not just treating active tuberculosis but also latent cases, and eliminating tuberculosis by 2050 worldwide is not possible, although great reductions in infections and deaths are possible. [3] Addressing poverty is a further requirement for eliminating tuberculosis.
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5] For latent tuberculosis, it is often used alone. [4]